Galer B - Search Results

1

Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain.

Hewitt DJ, Ho TW, Galer B, Backonja M, Markovitz P, Gammaitoni A, Michelson D, Bolognese J, Alon A, Rosenberg E, Herman G, Wang H. Hewitt DJ, et al. Among authors: galer b. Pain. 2011 Mar;152(3):514-521. doi: 10.1016/j.pain.2010.10.050. Epub 2010 Dec 23. Pain. 2011. PMID: 21185118 Clinical Trial.

2

Pain assessment and evaluation of patients who have neuropathic pain.

Backonja MM, Galer BS. Backonja MM, et al. Among authors: galer bs. Neurol Clin. 1998 Nov;16(4):775-90. doi: 10.1016/s0733-8619(05)70097-9. Neurol Clin. 1998. PMID: 9767062 Review.

3

Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study.

Galer BS, Rowbotham MC, Perander J, Friedman E. Galer BS, et al. Pain. 1999 Apr;80(3):533-538. doi: 10.1016/S0304-3959(98)00244-9. Pain. 1999. PMID: 10342414 Clinical Trial.

4

External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain.

Bruehl S, Harden RN, Galer BS, Saltz S, Bertram M, Backonja M, Gayles R, Rudin N, Bhugra MK, Stanton-Hicks M. Bruehl S, et al. Among authors: galer bs. Pain. 1999 May;81(1-2):147-54. doi: 10.1016/s0304-3959(99)00011-1. Pain. 1999. PMID: 10353502

5

Complex regional pain syndrome: are the IASP diagnostic criteria valid and sufficiently comprehensive?

Harden RN, Bruehl S, Galer BS, Saltz S, Bertram M, Backonja M, Gayles R, Rudin N, Bhugra MK, Stanton-Hicks M. Harden RN, et al. Among authors: galer bs. Pain. 1999 Nov;83(2):211-9. doi: 10.1016/s0304-3959(99)00104-9. Pain. 1999. PMID: 10534592

6

Complex regional pain syndrome: are there distinct subtypes and sequential stages of the syndrome?

Bruehl S, Harden RN, Galer BS, Saltz S, Backonja M, Stanton-Hicks M. Bruehl S, et al. Pain. 2002 Jan;95(1-2):119-24. doi: 10.1016/s0304-3959(01)00387-6. Pain. 2002. PMID: 11790474

7

The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale.

Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. Galer BS, et al. Clin J Pain. 2002 Sep-Oct;18(5):297-301. doi: 10.1097/00002508-200209000-00004. Clin J Pain. 2002. PMID: 12218500 Clinical Trial.

8

Pharmacokinetics and safety of continuously applied lidocaine patches 5%.

Gammaitoni AR, Alvarez NA, Galer BS. Gammaitoni AR, et al. Am J Health Syst Pharm. 2002 Nov 15;59(22):2215-20. doi: 10.1093/ajhp/59.22.2215. Am J Health Syst Pharm. 2002. PMID: 12455305 Clinical Trial.

9

A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain.

Wallace MS, Rowbotham MC, Katz NP, Dworkin RH, Dotson RM, Galer BS, Rauck RL, Backonja MM, Quessy SN, Meisner PD. Wallace MS, et al. Among authors: galer bs. Neurology. 2002 Dec 10;59(11):1694-700. doi: 10.1212/01.wnl.0000036273.98213.34. Neurology. 2002. PMID: 12473754 Clinical Trial.

10

Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature.

Gammaitoni AR, Alvarez NA, Galer BS. Gammaitoni AR, et al. J Clin Pharmacol. 2003 Feb;43(2):111-7. doi: 10.1177/0091270002239817. J Clin Pharmacol. 2003. PMID: 12616661 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters